195P REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis
Saved in:
Published in | Annals of oncology Vol. 33; p. S217 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Ltd
01.05.2022
|
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!